Group 1 - The company reported a revenue of RMB 299 million for the year ending December 31, 2024, representing a year-on-year growth of 43.82% [1] - The company incurred a loss attributable to shareholders of RMB 237 million [1] - Research and development expenditure amounted to RMB 135 million, reflecting a year-on-year increase of 4.39% [1] Group 2 - The company aims to provide automated, standardized, and intelligent assisted reproductive medical devices to improve success rates and operational efficiency for medical institutions [2] - The assisted reproductive technology sector is experiencing rapid development, with the company focusing on a "Live" core concept to deliver dynamic, real-time, and interconnected data experiences throughout the entire process [2] - The company has established a comprehensive product line covering the entire assisted reproduction industry chain, including reagents, consumables, instruments, and equipment, positioning itself as one of the few global suppliers with a full industry product offering [2]
贝康医疗-B(02170)发布年度业绩 收入2.99亿元 同比增长43.82% 全产业链布局与“Live”理念引领辅助生殖创新